Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

News SummaryMost relevantAll newsSector newsTweets 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2013 | 01:35pm CET

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
02/15 Purcell Julie & Lefkowitz LLP Is Investigating Impax Laboratories, Inc. for P..
02/06 IMPAX LABORATORIES : Research Reports Coverage on Drug Makers Stocks -- Sanofi, ..
02/02 IMPAX LABORATORIES : to Report Fourth Quarter and Full Year 2016 Results on Marc..
01/31 DIRECTOR DEALINGS : Impax Environmental Chairman Buys 10,000 Shares
01/25 IMPAX LABORATORIES : to Report Fourth Quarter and Full Year 2016 Results on Marc..
01/24 U.S. reaches settlement with Endo on pay-for-delay charges
01/23 IMPAX LABORATORIES : Endo Pharmaceuticals Inc. Agrees to Abandon Anticompetitive..
01/19 IMPAX LABORATORIES : software - hardware system IMPAX, the production of Agfa He..
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More news
Sector news : Pharmaceuticals - NEC
10:23aDJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
08:49aDJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
08:49aDJBAYER : CEO Still Upbeat on Deal -- WSJ
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22DJBAYER : Details Financing Plan for Monsanto Deal
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Teva's Got Potential - And The Complexity To Go With It
01/19 Kaleo undeterred by Mylan's trevails over EpiPen pricing; employing same cont..
01/17 Impax Laboratories Stock To Rise On New Catalyst
01/13 SANOFI : Key Threats In 2017 And Beyond
01/12 CVS Health to sell Impax Labs' generic epinephrine autoinjector for $109.99
Financials ($)
Sales 2016 846 M
EBIT 2016 144 M
Net income 2016 -126 M
Debt 2016 560 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 13,99
EV / Sales 2016 1,90x
EV / Sales 2017 1,55x
Capitalization 1 049 M
More Financials
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 18,5 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
J. Kevin Buchi President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results